TMCnet News
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine SummitCARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC. A live webcast will be available in the investor section of the company's website at www.designtx.com and will be archived for 30 days following the presentation. About Design Therapeutics Contact: |